enGene Therapeutics Inc. Research and Development Expense
enGene Therapeutics Inc. (ENGN) reported Research and Development Expense of $20.09 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-09-08
- enGene Therapeutics Inc. research and development expense for the quarter ending 2026-07-31 was $20.09M, a 11.01% decline year-over-year.
- enGene Therapeutics Inc. research and development expense for the quarter ending 2026-04-30 was $22.20M, a 9.83% increase year-over-year.
- enGene Therapeutics Inc. research and development expense for the quarter ending 2026-01-31 was $22.25M, a 11.42% increase year-over-year.
- enGene Therapeutics Inc. research and development expense for the quarter ending 2025-10-31 was $31.72M, a 181.40% increase year-over-year.
- enGene Therapeutics Inc. research and development expense for fiscal 2025 was $94.48M, a 146.59% increase from fiscal 2024.
- enGene Therapeutics Inc. research and development expense for fiscal 2024 was $38.31M, a 132.80% increase from fiscal 2023.
- enGene Therapeutics Inc. research and development expense for fiscal 2023 was $16.46M, a 6.41% increase from fiscal 2022.
- enGene Therapeutics Inc. research and development expense for fiscal 2022 was $15.47M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-07-31 | $20.09M 10-Q · filed 2026-09-08 | $42.28M derived: sum of 2 quarters · filed 2026-09-08 | $64.54M 10-Q · filed 2026-09-08 | $96.26M derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-04-30 | $22.20M 10-Q · filed 2026-06-15 | $44.45M 10-Q · filed 2026-06-15 | $76.17M derived: sum of 3 quarters · filed 2026-06-15 | $98.75M derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-01-31 | $22.25M 10-Q · filed 2026-03-09 | $53.98M derived: sum of 2 quarters · filed 2026-03-09 | $76.55M derived: sum of 3 quarters · filed 2026-09-08 | $96.76M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-10-31 | $31.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | $54.30M derived: sum of 2 quarters · filed 2026-09-08 | $74.51M derived: sum of 3 quarters · filed 2026-09-08 | $94.48M 10-K · filed 2025-12-22 |
| 2025-07-31 | $22.57M 10-Q · filed 2026-09-08 | $42.78M derived: sum of 2 quarters · filed 2026-09-08 | $62.76M 10-Q · filed 2026-09-08 | $74.03M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-04-30 | $20.21M 10-Q · filed 2026-06-15 | $40.18M 10-Q · filed 2026-06-15 | $51.46M derived: sum of 3 quarters · filed 2026-06-15 | $63.01M derived: sum of 4 quarters · filed 2026-06-15 |
| 2025-01-31 | $19.97M 10-Q · filed 2026-03-09 | $31.25M derived: sum of 2 quarters · filed 2026-03-09 | $42.80M derived: sum of 3 quarters · filed 2026-03-09 | $52.65M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-10-31 | $11.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | $22.82M derived: sum of 2 quarters · filed 2025-12-22 | $32.68M derived: sum of 3 quarters · filed 2025-12-22 | $38.31M 10-K · filed 2025-12-22 |
| 2024-07-31 | $11.55M 10-Q · filed 2025-09-11 | $21.40M derived: sum of 2 quarters · filed 2025-09-11 | $27.04M 10-Q · filed 2025-09-11 | $32.71M derived: sum of 4 quarters · filed 2025-09-11 |
| 2024-04-30 | $9.86M 10-Q · filed 2025-06-12 | $15.49M 10-Q · filed 2025-06-12 | $21.16M derived: sum of 3 quarters · filed 2025-06-12 | $25.07M derived: sum of 4 quarters · filed 2025-06-12 |
| 2024-01-31 | $5.64M 10-Q · filed 2025-03-10 | $11.31M derived: sum of 2 quarters · filed 2025-03-10 | $15.21M derived: sum of 3 quarters · filed 2025-03-10 | $18.43M derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-10-31 | $5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-19 | $9.57M derived: sum of 2 quarters · filed 2024-12-19 | $12.79M derived: sum of 3 quarters · filed 2024-12-19 | $16.46M 10-K · filed 2024-12-19 |
| 2023-07-31 | $3.90M 10-Q · filed 2024-09-10 | $7.12M derived: sum of 2 quarters · filed 2024-09-10 | $10.79M 10-Q · filed 2024-09-10 | |
| 2023-04-30 | $3.21M 10-Q · filed 2024-06-14 | $6.89M 10-Q · filed 2024-06-14 | ||
| 2023-01-31 | $3.67M 10-Q · filed 2024-03-11 | |||
| 2022-10-31 | $15.47M 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |